| Title | SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials |
| Authors | Tang, Huilin Dai, Qi Shi, Weilong Zhai, Suodi Song, Yiqing Han, Jiali |
| Affiliation | Peking Univ, Hosp 3, Dept Pharm, Beijing, Peoples R China. Indiana Univ, Dept Epidemiol, Richard M Fairbanks Sch Publ Hlth, 1050 Wishard Blvd, Indianapolis, IN 46202 USA. Indiana Univ, Ctr Pharmacoepidemiol, Richard M Fairbanks Sch Publ Hlth, Indianapolis, IN 46204 USA. Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Med,Med Ctr, Nashville, TN 37212 USA. Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA. Indiana Univ, Dept Epidemiol, Richard M Fairbanks Sch Publ Hlth, 1050 Wishard Blvd, Indianapolis, IN 46202 USA. Song, YQ Han, JL (reprint author), Indiana Univ, Ctr Pharmacoepidemiol, Richard M Fairbanks Sch Publ Hlth, Indianapolis, IN 46204 USA. Han, JL (reprint author), Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA. |
| Keywords | Cancer Meta-analysis Randomised controlled trials SGLT2 inhibitors Systematic review Type 2 diabetes PLACEBO-CONTROLLED TRIAL ADD-ON THERAPY METFORMIN PLUS SULFONYLUREA INADEQUATE GLYCEMIC CONTROL GLUCOSE COTRANSPORTER 2 CHRONIC KIDNEY-DISEASE DOUBLE-BLIND NETWORK METAANALYSIS JAPANESE PATIENTS LONG-TERM |
| Issue Date | 2017 |
| Publisher | DIABETOLOGIA |
| Citation | DIABETOLOGIA.2017,60(10),1862-1872. |
| Abstract | Aims/hypothesis The association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and the risk of cancer in individuals with type 2 diabetes remains uncertain. This study aimed to evaluate the risk of cancer associated with SGLT2 inhibitor treatment of type 2 diabetes. Methods We systematically searched PubMed, EMBASE, Cochrane Central Register of Controlled Trials and ClinicalTrials.gov from inception to 15 February 2017 to identify eligible randomised controlled trials (RCTs) that report cancer events in individuals with type 2 diabetes treated with SGLT2 inhibitors for at least 24 weeks. We performed pairwise and network meta-analyses as well as a cumulative meta-analysis to calculate ORs and 95% CIs. Results In total, 580 incidences of cancer among 34,569 individuals were identified from 46 independent RCTs with a mean trial duration of 61 weeks. When compared with comparators (placebo or other active glucose-lowering treatments), SGLT2 inhibitors were not significantly associated with an increased risk of overall cancer (OR 1.14 [95% CI 0.96, 1.36]). For pre-specified cancer types, the risk of bladder cancer might be increased with SGLT2 inhibitors (OR 3.87 [95% CI 1.48, 10.08]), especially empagliflozin (OR 4.49 [95% CI 1.21, 16.73]). Interestingly, canagliflozin might be protective against gastrointestinal cancers (OR 0.15 [95% CI 0.04, 0.60]). Conclusions/interpretation Current evidence from short-term RCTs did not indicate a significantly increased risk of overall cancer among individuals with type 2 diabetes using SGLT2 inhibitors. Given the short-term trial durations and uncertainty of evidence, future long-term prospective studies and postmarketing surveillance studies are warranted. |
| URI | http://hdl.handle.net/20.500.11897/470699 |
| ISSN | 0012-186X |
| DOI | 10.1007/s00125-017-4370-8 |
| Indexed | SCI(E) |
| Appears in Collections: | 第三医院 |
